T-Cell NK-Cell Engaging Bispecific Antibodies Market

Immunotherapy of cancer with T-cells oder NK cells is an area of great interest for the biopharmaceutical industry. Chimeric antigen receptor (CAR) engineered T-cell or NK cells represent one treatment modality under clinical evaluation, but the majority of Big Pharma prefers the engagement of T-cells or NK cells by recombinant monoclonal antibodies as off-the-shelf products. As only a few major pharmaceutical companies have clinically validated in-house bispecific antibody technology, partnering with technology providing companies is of great importance.
T-Cell NK-Cell Engaging Bispecific Antibodies Market contains market size and forecasts of T-Cell & NK-Cell Engaging Bispecific Antibodies in global, including the following market information:
Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Sales, 2017-2022, 2023-2028, (ml)
Global top five T-Cell & NK-Cell Engaging Bispecific Antibodies companies in 2021 (%)
The global T-Cell & NK-Cell Engaging Bispecific Antibodies market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Recombinant Monoclonal Antibodies Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of T-Cell & NK-Cell Engaging Bispecific Antibodies include AbbVie, Astellas Pharma, GEMoaB Monoclonals, Immunocore, Molecular Partners, Roche, AstraZeneca, Merck & Co. and Pfizer, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the T-Cell & NK-Cell Engaging Bispecific Antibodies manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (ml)
Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Segment Percentages, by Type, 2021 (%)
Recombinant Monoclonal Antibodies
In-House Bispecific Antibodies
Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (ml)
Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Segment Percentages, by Application, 2021 (%)
Immunotherapy of Cancer
Clinical Experiment
Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (ml)
Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies T-Cell & NK-Cell Engaging Bispecific Antibodies revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies T-Cell & NK-Cell Engaging Bispecific Antibodies revenues share in global market, 2021 (%)
Key companies T-Cell & NK-Cell Engaging Bispecific Antibodies sales in global market, 2017-2022 (Estimated), (ml)
Key companies T-Cell & NK-Cell Engaging Bispecific Antibodies sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
AbbVie
Astellas Pharma
GEMoaB Monoclonals
Immunocore
Molecular Partners
Roche
AstraZeneca
Merck & Co.
Pfizer
Eli Lilly
IGM Biosciences
Novartis
BenHealth Biopharmaceuticals
CytomX Therapeutics
Janssen
Lava Therapeutics
MacroGenics
Maverick Therapeutics
VBL Therapeutics
Amgen